MA41788A - Modulation de l'immunité tumorale par proteines médiatrices de la délivrance d'o2 - Google Patents
Modulation de l'immunité tumorale par proteines médiatrices de la délivrance d'o2Info
- Publication number
- MA41788A MA41788A MA041788A MA41788A MA41788A MA 41788 A MA41788 A MA 41788A MA 041788 A MA041788 A MA 041788A MA 41788 A MA41788 A MA 41788A MA 41788 A MA41788 A MA 41788A
- Authority
- MA
- Morocco
- Prior art keywords
- mediatory
- proteins
- modulation
- delivery
- tumor immunity
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000036039 immunity Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134523P | 2015-03-17 | 2015-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41788A true MA41788A (fr) | 2021-03-31 |
Family
ID=56297072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041788A MA41788A (fr) | 2015-03-17 | 2016-03-17 | Modulation de l'immunité tumorale par proteines médiatrices de la délivrance d'o2 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180243364A1 (fr) |
| EP (1) | EP3270961A2 (fr) |
| JP (2) | JP7049832B2 (fr) |
| KR (1) | KR20170132789A (fr) |
| CN (1) | CN107580499A (fr) |
| AU (1) | AU2016232866B2 (fr) |
| CA (1) | CA2979974A1 (fr) |
| HK (2) | HK1249416A1 (fr) |
| IL (1) | IL254507B (fr) |
| MA (1) | MA41788A (fr) |
| MX (1) | MX2017011847A (fr) |
| RU (1) | RU2731450C2 (fr) |
| SG (2) | SG10201908269SA (fr) |
| WO (1) | WO2016149562A2 (fr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2886531T3 (es) * | 2013-01-07 | 2021-12-20 | Omniox Inc | Formas poliméricas de proteínas H-NOX |
| CA2979974A1 (fr) | 2015-03-17 | 2016-09-22 | Omniox, Inc. | Modulation de l'immunite tumorale par distribution d'o2 induite par une proteine |
| CN119950689A (zh) * | 2016-07-05 | 2025-05-09 | 北极星药业集团股份有限公司 | 使用精氨酸耗竭剂的组合癌症免疫疗法 |
| EP3836911A1 (fr) * | 2018-08-15 | 2021-06-23 | Omniox, Inc. | Protéines h-nox pour le traitement d'affections cardiovasculaires et pulmonaires |
| WO2020263830A1 (fr) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Protéines de fusion flt3l-fc et procédés d'utilisation |
| ES2973832T3 (es) | 2019-10-18 | 2024-06-24 | Forty Seven Inc | Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda |
| JP2022552748A (ja) | 2019-10-31 | 2022-12-19 | フォーティ セブン， インコーポレイテッド | 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| IL297327B2 (en) | 2020-05-01 | 2026-01-01 | Gilead Sciences Inc | 4,2-dioxopyrimidine compounds CD73 inhibitors |
| WO2022221431A1 (fr) * | 2021-04-14 | 2022-10-20 | OncoC4, Inc. | Utilisation d'inhibiteurs de hif-1-alpha en immunothérapie anticancéreuse |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022245671A1 (fr) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Méthodes d'utilisation de protéines de fusion flt3l-fc |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023178181A1 (fr) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations |
| KR20240165995A (ko) | 2022-03-24 | 2024-11-25 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암의 치료를 위한 병용요법 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| EP4531847A4 (fr) * | 2022-05-31 | 2025-12-24 | Cardiff Oncology Inc | Traitement du cancer à l'aide d'inhibiteurs de topoisomérase i et d'inhibiteurs de plk1 |
| KR20250028371A (ko) | 2022-07-01 | 2025-02-28 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| WO2024064668A1 (fr) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | POLYTHÉRAPIE ANTICANCÉREUSE PAR RAYONNEMENT IONISANT FOCAL ET PERTURBATION CD47/SIRPα |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CR20250446A (es) | 2023-04-21 | 2025-12-02 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121620513A (zh) | 2023-07-26 | 2026-03-06 | 吉利德科学公司 | Parp7抑制剂 |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (fr) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Inhibiteurs azaspiro de wrn |
| WO2025245003A1 (fr) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5248766A (en) | 1990-08-17 | 1993-09-28 | Baxter International Inc. | Oxirane-modified hemoglobin based composition |
| US5295944A (en) * | 1991-05-14 | 1994-03-22 | Dana-Farber Cancer Institute | Method for treating a tumor with ionizing radiation |
| US5776898A (en) | 1991-05-14 | 1998-07-07 | Dana-Farber Cancer Institute | Method for treating a tumor with a chemotherapeutic agent |
| WO1992020369A1 (fr) | 1991-05-14 | 1992-11-26 | Dana Farber Cancer Institute | Utilisation d'hemoglobine dans un procede de traitement de tumeurs a l'aide d'agents chimiotherapeutiques |
| ATE302019T1 (de) | 1997-02-28 | 2005-09-15 | Univ California | Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen |
| US5981710A (en) | 1997-07-21 | 1999-11-09 | Baxter International, Inc. | Therapeutic hemoglobin composition having isotropically increased size |
| US20020142957A1 (en) * | 2000-08-07 | 2002-10-03 | Hepler William T. | Compositions and methods for the therapy and diagnosis of colon cancer |
| US20030153491A1 (en) | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| EP1850852A4 (fr) | 2005-02-22 | 2009-11-18 | Cedars Sinai Medical Center | Utilisation du sildenafil, du vardenafil et d'autres inhibiteurs de la 5-phosphodiesterase pour augmenter la permeabilite d'une barriere sang /cerveau anormale |
| PL1981519T3 (pl) | 2005-12-29 | 2018-07-31 | Dyax Corp. | Hamowanie proteaz |
| JP2009537145A (ja) | 2006-05-15 | 2009-10-29 | バイラル ロジック システムズ テクノロジー コーポレーション | 免疫学的疾患および障害を治療するためのｃｄ４７と関連した組成物および方法 |
| NZ594457A (en) | 2006-05-22 | 2013-06-28 | Univ California | Compositions and methods for the delivery of oxygen |
| JP2010503418A (ja) | 2006-09-19 | 2010-02-04 | ドイチェス クレープスフォルシュングスツェントルム | 細胞死受容体ＣＤ９５による成体神経幹細胞の神経発生のｉｎｖｉｖｏおよびｉｎｖｉｔｒｏでの制御 |
| EP2094291A1 (fr) | 2006-12-21 | 2009-09-02 | Novo Nordisk A/S | Ligands des récepteurs de la prolactine dimères |
| US20110288023A1 (en) * | 2007-06-08 | 2011-11-24 | The Regents Of The University Of California Office Of Technology Transfer | Cancer drug delivery using modified transferrin |
| US20100183545A1 (en) * | 2008-10-14 | 2010-07-22 | The United States Of America, As Represented By The Secretary, | Targeted cargo protein combination therapy |
| JP2011168521A (ja) * | 2010-02-18 | 2011-09-01 | Eci Inc | ＰＥＧ化ｅＭＩＰ及びその製造方法並びにこれを用いた癌治療剤 |
| US20110243849A1 (en) | 2010-04-02 | 2011-10-06 | Marletta Michael A | Heme-binding photoactive polypeptides and methods of use thereof |
| US8742073B2 (en) | 2010-05-27 | 2014-06-03 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
| US7989593B1 (en) * | 2010-05-27 | 2011-08-02 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
| DK2661275T3 (en) | 2011-01-07 | 2019-04-15 | Poseida Therapeutics Inc | COMPOSITIONS AND METHODS FOR ADMINISTRATING THE HIGH OXYGEN EFFICIENCY TO TUMORS FOR THE ADMINISTRATION |
| US20140363496A1 (en) | 2011-01-07 | 2014-12-11 | Vindico NanoBio Technology Inc. | Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization of Tumors |
| US20130052232A1 (en) | 2011-08-31 | 2013-02-28 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
| ES2886531T3 (es) | 2013-01-07 | 2021-12-20 | Omniox Inc | Formas poliméricas de proteínas H-NOX |
| WO2014182761A1 (fr) * | 2013-05-09 | 2014-11-13 | Mayo Foundation For Medical Education And Research | Traitement de patients en fonction des sous-types immunitaires |
| ES2822665T3 (es) * | 2013-05-31 | 2021-05-04 | Merck Sharp & Dohme | Terapias de combinación para el cáncer |
| PE20170255A1 (es) * | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| ES2822557T3 (es) | 2014-08-08 | 2021-05-04 | Poseida Therapeutics Inc | Composiciones y su uso para inducir la embolización microvascular de tumores mediada por nanopartículas |
| WO2016090111A1 (fr) | 2014-12-05 | 2016-06-09 | Vindico NanoBio Technology Inc. | Compositions et méthodes pour l'induction de l'embolisation microvasculaire de tumeurs par des nanoparticules |
| CA2979974A1 (fr) | 2015-03-17 | 2016-09-22 | Omniox, Inc. | Modulation de l'immunite tumorale par distribution d'o2 induite par une proteine |
-
2016
- 2016-03-17 CA CA2979974A patent/CA2979974A1/fr active Pending
- 2016-03-17 CN CN201680027143.9A patent/CN107580499A/zh active Pending
- 2016-03-17 MA MA041788A patent/MA41788A/fr unknown
- 2016-03-17 RU RU2017134953A patent/RU2731450C2/ru active
- 2016-03-17 US US15/558,957 patent/US20180243364A1/en not_active Abandoned
- 2016-03-17 IL IL254507A patent/IL254507B/en unknown
- 2016-03-17 KR KR1020177029648A patent/KR20170132789A/ko not_active Ceased
- 2016-03-17 HK HK18108922.6A patent/HK1249416A1/zh unknown
- 2016-03-17 SG SG10201908269S patent/SG10201908269SA/en unknown
- 2016-03-17 HK HK18109475.5A patent/HK1250137A1/zh unknown
- 2016-03-17 AU AU2016232866A patent/AU2016232866B2/en active Active
- 2016-03-17 MX MX2017011847A patent/MX2017011847A/es unknown
- 2016-03-17 SG SG11201707583RA patent/SG11201707583RA/en unknown
- 2016-03-17 EP EP16734059.5A patent/EP3270961A2/fr active Pending
- 2016-03-17 JP JP2017549034A patent/JP7049832B2/ja active Active
- 2016-03-17 WO PCT/US2016/022981 patent/WO2016149562A2/fr not_active Ceased
-
2020
- 2020-08-04 JP JP2020132260A patent/JP2020183450A/ja active Pending
-
2021
- 2021-12-10 US US17/547,748 patent/US12285463B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20220160823A1 (en) | 2022-05-26 |
| CA2979974A1 (fr) | 2016-09-22 |
| RU2731450C2 (ru) | 2020-09-03 |
| KR20170132789A (ko) | 2017-12-04 |
| EP3270961A2 (fr) | 2018-01-24 |
| HK1250137A1 (zh) | 2018-11-30 |
| SG11201707583RA (en) | 2017-10-30 |
| IL254507B (en) | 2022-07-01 |
| RU2017134953A (ru) | 2019-04-08 |
| US20180243364A1 (en) | 2018-08-30 |
| WO2016149562A2 (fr) | 2016-09-22 |
| JP2020183450A (ja) | 2020-11-12 |
| SG10201908269SA (en) | 2019-10-30 |
| JP2018511595A (ja) | 2018-04-26 |
| MX2017011847A (es) | 2018-06-06 |
| IL254507A0 (en) | 2017-11-30 |
| AU2016232866B2 (en) | 2021-10-21 |
| CN107580499A (zh) | 2018-01-12 |
| BR112017019862A2 (pt) | 2018-05-29 |
| WO2016149562A3 (fr) | 2016-11-03 |
| JP7049832B2 (ja) | 2022-04-07 |
| HK1249416A1 (zh) | 2018-11-02 |
| RU2017134953A3 (fr) | 2019-12-26 |
| US12285463B2 (en) | 2025-04-29 |
| AU2016232866A1 (en) | 2017-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41788A (fr) | Modulation de l'immunité tumorale par proteines médiatrices de la délivrance d'o2 | |
| IL291932B2 (en) | Nanoparticle compositions for sustained therapy | |
| IL254516B (en) | Proteins specific for cd137 | |
| EP3307378A4 (fr) | Thérapie de modulation intratumorale | |
| IL263846B (en) | Formulation of a peptide vaccine | |
| EP3317294A4 (fr) | Peptides stabilisés anti-microbiens | |
| MA47323A (fr) | Protéines de liaison icos | |
| EP3370760A4 (fr) | Thérapie de substitution de plasminogène destinée au déficit en plasminogène | |
| FR3018450B1 (fr) | Procede de preparation de proteines plasmatiques humaines | |
| HUE053347T2 (hu) | Glikopeptid-készítmények | |
| EP3665416A4 (fr) | Lampe de sécurité | |
| LT3143037T (lt) | Alfa4beta7 integrino tioeterio peptidų antagonistaii | |
| EP3522947C0 (fr) | Dispositif transcathéter pour la pose de dispositifs intracorporels | |
| HUE051184T2 (hu) | Baktériumalapú fehérjeszállítás | |
| EP3589640A4 (fr) | Purification de protéines avec la protéine l | |
| HUE045024T2 (hu) | Poliamid készítmények | |
| EP3355931C0 (fr) | Conjugués de protéines | |
| HUE063435T2 (hu) | Eljárások rekombináns fehérjék mannóztartalmának növelésére | |
| EP3436049A4 (fr) | Protéine 8 de type angiopoïétine (angptl8) | |
| DK3259358T3 (da) | Forøget proteinekspression | |
| EP3405581A4 (fr) | Protéines antimicrobiennes | |
| EP3697428A4 (fr) | Peptides sécréteurs artificiels pour la production de protéines hétérologues | |
| DK3615169T3 (da) | Separeringslegeme | |
| EP3463414C0 (fr) | Interfaces de protéines | |
| EP3377633C0 (fr) | Production de protéines recombinantes |